MedTrace Logo

Evaluating Nulojix (Belatacept) Long-Term Safety in Transplant

NCT01386359 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 914

Last updated 2022-06-06

No results posted yet for this study

Summary

To describe how Nulojix (belatacept) is used and to determine how often Post-Transplant Lymphoproliferative Disorder (PTLD), Central Nervous System (CNS) PTLD and Progressive Multifocal Leukoencephalopathy (PML), rare and serious complications of transplant treatment, occur in patients taking Nulojix (belatacept) in a real-world setting.

Conditions

  • Kidney Transplantation

Interventions

DRUG

No Intervention

No Intervention. Subjects are previously treated with Nulojix (belatacept)

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2019-04-30
Completion
2019-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01386359 on ClinicalTrials.gov